Weighing the Odds: Novel β-Lactam/β-Lactamase Inhibitor Use in Hospital-Acquired and Ventilator-Associated Pseudomonas aeruginosa Pneumonia for Patients Who Are Morbidly Obese

BACKGROUND: Pseudomonas aeruginosa is a leading cause of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP). Novel β-lactam/β-lactamase inhibitor (BL/BLI) combinations are often used for these infections; however, limited data exist to guide the dosing of BL/BLI in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Kunz Coyne, Ashlan J, Orzol, Carolina, Veve, Michael P, Rybak, Michael J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500045/
https://www.ncbi.nlm.nih.gov/pubmed/37720698
http://dx.doi.org/10.1093/ofid/ofad454

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500045/
https://www.ncbi.nlm.nih.gov/pubmed/37720698
http://dx.doi.org/10.1093/ofid/ofad454

Ejemplares similares